Medicinal effect and its JP2/RyR2-based mechanism of Smilax glabra flavonoids on angiotensin II-induced hypertrophy model of cardiomyocytes
Y Cai, J Tu, S Pan, J Jiang, Q Shou, Y Ling… - Journal of …, 2015 - Elsevier
Ethnopharmacological relevance Rhizome and root of Smilax glabra Roxb (Liliaceae family)
is a widely used traditional Chinese medicine (TCM) named Tu-fu-ling (TFL) for cardiac …
is a widely used traditional Chinese medicine (TCM) named Tu-fu-ling (TFL) for cardiac …
Effects of Wenxin Keli on cardiac hypertrophy and arrhythmia via regulation of the calcium/calmodulin dependent kinase II signaling pathway
X Yang, Y Chen, Y Li, X Ren, Y Xing… - BioMed Research …, 2017 - Wiley Online Library
We investigated the effects of Wenxin Keli (WXKL) on the Calcium/Calmodulin dependent
kinase II (CaMK II) signal transduction pathway with transverse aortic constriction (TAC) rats …
kinase II (CaMK II) signal transduction pathway with transverse aortic constriction (TAC) rats …
High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3
R Guo, N Liu, H Liu, J Zhang, H Zhang, Y Wang… - Phytomedicine, 2020 - Elsevier
Background: Cardiac hypertrophy is a prominent feature of heart remodeling, which may
eventually lead to heart failure. Tongmaiyangxin (TMYX) pills are a clinically used botanical …
eventually lead to heart failure. Tongmaiyangxin (TMYX) pills are a clinically used botanical …
Isoliquiritigenin attenuates pathological cardiac hypertrophy via regulating AMPKα in vivo and in vitro
M Gao, Q Cai, H Si, S Shi, H Wei, M Lv, X Wang… - Journal of Molecular …, 2022 - Springer
Isoliquiritigenin (ISL) is a type of flavonoid, derived from the root of the legume plant
Glycyrrhiza, that has multiple pharmacological properties. However, its role in cardiac …
Glycyrrhiza, that has multiple pharmacological properties. However, its role in cardiac …
[HTML][HTML] Puerarin attenuates cardiac hypertrophy partly through increasing mir-15b/195 expression and suppressing non-canonical transforming growth factor beta …
X Zhang, Y Liu, Q Han - Medical Science Monitor: International …, 2016 - ncbi.nlm.nih.gov
Background Previous studies demonstrated that puerarin has therapeutic effects on cardiac
hypertrophy. This study aimed to explore whether the effect of puerarin on attenuating …
hypertrophy. This study aimed to explore whether the effect of puerarin on attenuating …
[HTML][HTML] The protective effects of the miR-129-5p/keap-1/Nrf2 axis on Ang II-induced cardiomyocyte hypertrophy
H Ye, G Xu, D Zhang, R Wang - Annals of Translational Medicine, 2021 - ncbi.nlm.nih.gov
Background Cardiac hypertrophy is a common pathological process in many cardiac
diseases, and persistent cardiac hypertrophy is the main cause of heart failure and sudden …
diseases, and persistent cardiac hypertrophy is the main cause of heart failure and sudden …
The inhibitory effect of WenxinKeli on H9C2 cardiomyocytes hypertrophy induced by angiotensin II through regulating autophagy activity
J Li, Y Li, Y Zhang, D Hu, Y Gao… - … Medicine and Cellular …, 2017 - Wiley Online Library
Objectives. We investigated the role of cardiomyocyte autophagy and its regulatory
mechanisms by WenxinKeli (WXKL) in cells subjected to hypertrophy. Methods. H9C2 …
mechanisms by WenxinKeli (WXKL) in cells subjected to hypertrophy. Methods. H9C2 …
The novel peptide athycaltide-1 attenuates Ang II-induced pathological myocardial hypertrophy by reducing ROS and inhibiting the activation of CaMKII and ERK1/2
X Zheng, F Su, M Lei, J Li, C Zhang, Y Zhang… - European Journal of …, 2023 - Elsevier
Pathological myocardial hypertrophy initially develops as an adaptive response to cardiac
stress, which can be induced by many diseases. It is accompanied by adverse …
stress, which can be induced by many diseases. It is accompanied by adverse …
QiShenYiQi pill ameliorates cardiac fibrosis after pressure overload-induced cardiac hypertrophy by regulating FHL2 and the macrophage RP S19/TGF-β1 signaling …
G Anwaier, TT Xie, CS Pan, AQ Li, L Yan… - Frontiers in …, 2022 - frontiersin.org
Purpose: Heart failure (HF) is a leading cause of morbidity and mortality worldwide, and it is
characterized by cardiac hypertrophy and fibrosis. However, effective treatments are not …
characterized by cardiac hypertrophy and fibrosis. However, effective treatments are not …
Qiliqiangxin Capsule Modulates Calcium Transients and Calcium Sparks in Human Induced Pluripotent Stem Cell‐Derived Cardiomyocytes
Y Li, Z Zhang, X Hao, T Yu, S Li - … ‐Based Complementary and …, 2022 - Wiley Online Library
Background. The therapeutic effects of Qiliqiangxin capsule (QLQX), a Chinese patent
medicine, in patients with chronic heart failure are well established. However, whether …
medicine, in patients with chronic heart failure are well established. However, whether …